Skip to main content
Lilly says next-gen diabetes drug performing well in clinical trial

Eli Lilly and Co. recently released positive results from a Phase IIb clinical trial of its dual GIP and GLP-1 receptor agonist diabetes treatment, but analysts say the drug will not be marketed until 2023, giving Novo Nordisk time to develop a competing product.

Full Story: